Aclaris Therapeutics, Inc.
ACRS
$4.88
-$0.07-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 46.50% | 50.84% | -282.88% | -129.47% | -68.53% |
| Total Depreciation and Amortization | -38.15% | -43.74% | -44.51% | -39.48% | -23.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -85.84% | -85.35% | 1,530.95% | 3,314.14% | 8,278.65% |
| Change in Net Operating Assets | -83.43% | -75.54% | -106.18% | 755.29% | 276.42% |
| Cash from Operations | -323.85% | -134.68% | -139.80% | 84.50% | 83.08% |
| Capital Expenditure | -179.31% | 8.26% | 84.52% | 90.09% | 96.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.62% | 169.60% | -287.10% | -208.45% | -276.83% |
| Cash from Investing | 97.50% | 169.32% | -291.39% | -209.81% | -281.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -27.49% | -- | 8,720.29% | 8,892.36% | 189.61% |
| Repurchase of Common Stock | 33.07% | -9.05% | -711.84% | -273.21% | -300.64% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.47% | -6.47% | -884.38% | -515.86% | -515.86% |
| Cash from Financing | -29.77% | -107.86% | 1,424,940.00% | 71,559.62% | 178.85% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 69.06% | 69.89% | -360.07% | 130.88% | 38.25% |